COVID-Associated Mucormycosis: Review of Cases Reported Worldwide and in India
Abstract
Objective: The aim of this review literature is to collate and analyse various case reports and series reporting mucormycosis in COVID and post-COVID patients in India and worldwide.
Methods: A systematic literature search was conducted from December 2019 to June 2021 using keywords. Details of all the case reports/ series that reported rhino-orbital-cerebral mucormycosis in COVID and post-COVID settings were retrieved and analysed.
Results: In this systematic review, 33 articles were included and a total of 181 cases of mucormycosis in COVID and post-COVID patients were reported. Mucormycosis was predominantly seen in males (71.2%) as compared to females (28.7%). History of steroid use was present in 113 patients (62.4%). Type 2 diabetes mellitus was the most common independent risk factor, present in 138 patients (76%). Sino-nasal involvement was seen in 27 patients (14.9%), rhino-orbital involvement in 114 patients (62.9%), andrhino-orbital-cerebral involvement was observed in 40 patients (22%). Improvement in clinical status was observed in 106 patients (58.5%) while 38 patients (21%) expired.
Conclusions: A rapid rise in cases of mucormycosis had been reported in the COVID era. Unwarranted use of steroids coupled with uncontrolled hyperglycemia, unregulated activation of inflammatory mediators and overactivation of entry-point receptors inflicted by the Coronavirus cause a state of immune dysregulation, leading to opportunistic invasive fungal infections. A delay in diagnosis can result in disfigurement, functional loss, or even death. Multidisciplinary management with prompt reversal of risk factors is recommended.
How to cite this article:
Nair RR, Sahoo AK, Sharma A. COVID-Associated Mucormycosis: Review of Cases Reported Worldwide and in India. J Adv Res Med. 2022;9(2):18-26.
DOI: https://doi.org/10.24321/2349.7181.202210
References
Velavan TP, Meyer CG. The COVIDâ€19 epidemic. Trop Med Int Health. 2020;25(3):278-80. [PubMed] [Google Scholar]
Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523. [PubMed] [Google Scholar]
Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir Med. 2021;9(8):e77. [PubMed] [Google Scholar]
Saldanha M, Reddy R, Vincent MJ. Paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg. 2022;74 (Suppl 2):3407-10. [PubMed] [Google Scholar]
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442-7. [PubMed] [Google Scholar]
Dronamraju S, Nimkar S, Damke S, Agrawal S, Kumar S. Angioinvasion of anterior cerebral artery by rhinocerebral mucormycosis leading to intraparenchymal hemorrhage: a rare case report. Medical Sci. 2021;25(111):1088-91. [Google Scholar]
Sebastian SK, Kumar VB, Gupta M, Sharma Y. Covid associated invasive fungal sinusitis. Indian J Otolaryngol Head Neck Surg. 2022;74 (Suppl 2):2883-6. [PubMed] [Google Scholar]
Revannavar SM, Supriya PS, Samaga L, Vineeth VK. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 2021;1;14(4):e241663. [PubMed] [Google Scholar]
Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021 Apr;69(4):1002. [PubMed] [Google Scholar]
Shirke PD, Chitguppi R. Post-covid jaw osteomyelitis: a case series. J Indian Dent Assoc. 2021;15(5). [Google Scholar]
Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9). [PubMed] [Google Scholar]
Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69(2):244-52. [PubMed] [Google Scholar]
Patil S, Sarate D, Chopade S, Khade M, Dhage S, Kangate S. Emerging challenge of mucormycosis in post-COVIDpatients. IAR J Med Case Rep. 2021;2(3).
Deshmukh R, Upadhyay K, Patwadkar R, Patil S. Mucormycosis in COVID-19. J Adv Res Med. 2020;7(3):20-3. [Google Scholar]
Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, Rao PS, Haldipur D, Bonanthaya K. SARSCoV-2, uncontrolled diabetes and corticosteroids - an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021;20(3):418-25. [PubMed] [Google Scholar]
Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep. 2021;82:105957. [PubMed] [Google Scholar]
Satish D, Joy D, Ross A, Balasubramanya B. Mucormycosis coinfection associated with global COVID-19: a case series from India. Int J Otorhinolaryngol Head Neck Surg. 2021;7(5):815-20.
Mishra N, Mutya VS, Thomas A, Rai G, Reddy B, Mohanan AA, Ray S, Thiruvengadem AV, Siddini V, Hegde R. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg. 2021;7(5):867-70. [Google Scholar]
Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in postâ€COVIDâ€19 renal transplant patients: a lethal complication in followâ€up. Transpl Infect Dis. 2021;23(4):e13663. [PubMed] [Google Scholar]
Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021;69(6):1563-8. [PubMed] [Google Scholar]
Nehara HR, Puri I, Singhal V, Sunil IH, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India.Indian J Med Microbiol. 2021;39(3):380-3. [PubMed] [Google Scholar]
Shah D, Talwar D, Kumar S, Acharya S, Dubey A. Mucormycosis as a complication of LONG COVID: a case series. J Med Sci. 2021;25(112):1331-7. [Google Scholar]
Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features. Indian J Ophthalmol. 2021;69(6):1627-30. [PubMed] [Google Scholar]
Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, Simko JP, Winn BJ. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast Reconstr Surg. 2021;37(2):e40-e80. [PubMed] [Google Scholar]
Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.e5-264.e8. [PubMed] [Google Scholar]
Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021;13(2):e13163. [PubMed] [Google Scholar]
Pauli M, Pereira L, Monteiro M, de Camargo A, Rabelo G. Painful palatal lesion in a COVID-19 patient. Oral Surg Oral Med Oral Pathol Oral Radio. 2021;28. [Google Scholar]
Tabarsi P, Khalili N, Pourabdollah M, Sharifynia S, Safavi Naeini A, Ghorbani J, Mohamadnia A, Abtahian Z, Askari E. COVID 19 associated rhinosinusitis mucormycosis due to Rhizopus oryzae: a rare but potentially fatal infection occurring after treatment with corticosteroids. Am J Trop Med Hyg. 2021;105(2):449-53. [PubMed] [Google Scholar]
Karimiâ€Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVIDâ€19).Int Forum Allergy Rhinol. 2021;11(6):1029-30. [PubMed] [Google Scholar]
Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, Mirhendi H, Salehi M, Tabari A, Mohammadi Ardehali M, Kord M, Roilides E, Rezaie S. The doubleedged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenzaâ€associated mucormycosis versus COVIDâ€19 associated mucormycosis. Mycoses. 2021;64(8):798-808. [PubMed] [Google Scholar]
Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol. 2022;32(4):NP11-6. [PubMed] [Google Scholar]
Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021;12(3):85-9. [PubMed] [Google Scholar]
Sargin F, Akbulut M, Karaduman S, Sungurtekin H. Severe rhinocerebral mucormycosis case developed after COVID 19. J Bacteriol Parasitol. 2021;12(1):1000386. [Google Scholar]
Arana C, Cuevas RamÃrez RE, Xipell M, Casals J, Moreno A, Herrera S, Bodro M, Cofan F, Diekmann F, Esforzado N. Mucormycosis associated with covid19 in two kidney transplant patients. Transpl Infect Dis. 2021;23(4):e13652. [PubMed] [Google Scholar]
Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih S, Alijani N, Barac A, Abdollahi A, Khodavaisy S. Mucormycosis in patients with COVIDâ€19: a crossâ€sectional descriptive multicentre study from Iran. Mycoses. 2021;64(10):1238-52. [PubMed] [Google Scholar]
Farid HA, Hashim AR, Hasrat NH. Rhinocerebral mucormycosis as a COVID-19-related complication: a case report from Basra City, Southern Iraq. J Glob Sci Res. 2021;6(5):1369-74. [Google Scholar]
Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbio. 2013;8(9):1163-75. [PubMed] [Google Scholar]
Wikidoc [Internet]. Mucormycosis historical perspective; [cited 2021 Jul 24]. Available from: https://www.wikidoc.org/index.php/Mucormycosis_historical_perspective
Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, Pamidimukkala U, Jillwin J, Varma S, Das A, Panda NK, Singh S, Bal A, Chakrabarti A. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395-402. [PubMed] [Google Scholar]
Zeichner LO, Smith M, McGinnis MR. Zygomycosis. In: Anaissie E, McGinnis M, Pfaller M, editors. Clinical mycology. 2nd ed. New York: Churchill Livingstone Elsevier. p 297-305.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012 Feb;54(suppl_1):S23-34. [PubMed] [Google Scholar]
Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523. [PubMed] [Google Scholar]
Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, Singh R, Shastri P, Umabala P, Sardana R, Kindo A, Capoor MR, Mohan S, Muthu V, Agarwal R, Chakrabarti A. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944-e9. [PubMed] [Google Scholar]
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54Suppl 1(Suppl 1):S16-S22. [PubMed] [Google Scholar]
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146. [PubMed] [Google Scholar]
Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-the bitter and the sweet. PLoS Pathog. 2017;13(8):e1006408. [PubMed] [Google Scholar]
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-53. [PubMed] [Google Scholar]
Therakathu J, Prabhu S, Irodi A, Sudhakar SV, Yadav VK, Rupa V. Imaging features of rhinocerebral mucormycosis: a study of 43 patients. Egypt J Radiol Nucl Med. 2018;49(2):447-52. [Google Scholar]
Gamba JL, Woodruff WW, Djang WT, Yeates AE. Craniofacial mucormycosis: assessment with CT. Radiology. 1986;160(1):207-12. [PubMed] [Google Scholar]
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019 Dec;19(12):e405-e1. [PubMed] [Google Scholar]
Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses. 2001;44(7â€8):253-60. [PubMed] [Google Scholar]
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
